Baar, 13.06.2019 (PresseBox) – CorFlow Therapeutics AG („CorFlow“) announced that the US Patent Office (USPTO) this week granted the company it’s first US patent, US Patent No. 10,315,016 „System and methods for treating MVO“, which protects CorFlow’s Controlled Flow Infusion (CoFI™) method for diagnosing and provide a treatment platform for microvascular obstruction (MVO). The patent protects several specific methods of measuring microvascular function parameters that determine therapeutic effectiveness in the cardiac catheterisation laboratory (cath lab) immediately following the MVO treatment.
The three co-Founders of CorFlow, Dr. Robert S. Schwartz, Prof. Martin T. Rothman and Jon H. Hoem, are the inventors.
By issuing this patent, the US Patent Office has protected the CoFI™ technology until 2037 in the United States.
Dr. Schwartz commented on the newly issued patent: „This patent is an important cornerstone in CorFlow’s overall patent strategy. In addition to protecting the innovative method of treating microvascular obstruction, it also provides technology descriptions and methods for MVO diagnosis and treatment which will be pursued in the continuation filings following the grant of this patent.“
CorFlow has filed multiple other patent applications in major markets including the United States, Europe, China and Japan. These patent applications seek to protect the CorFlow diagnostic MVO measurements in the cath lab as well as additional technology implementations of the CoFI™ System. The company is very optimistic about securing patent rights in the targeted markets, thus building a solid IP portfolio for it’s business. CorFlow is represented by two leading US medical device patent offices based in Minneapolis (MN, USA).
Unternehmen: CorFlow Therapeutics AG
Den Originalartikel finden Sie auf www.pressebox.de